Abstract: Application of Derivatives of Clostridium ghonii, especially in the application of Derivatives of Clostridium ghonii MW-DCG-HNCv-18 in preparation of medicines for treating non-small cell lung carcinoma. It also discloses a medicine combining the Derivatives of Clostridium ghonii MW-DCG-HNCv-18 strain with Docetaxel as the active ingredients. According to the invention, the MW-DCG-HNCv-18 strain is found to have specific inhibition effect on non-small cell lung carcinoma for the first time, the inhibition effect on the non-small cell lung carcinoma is significantly superior to that of other known similar strains, and through screening, the MW-DCG-HNCv-18 strain is found to have more prominent inhibition effect on non-small cell lung carcinoma when combined with Docetaxel injection.
Abstract: The present invention relates to a derivative bacterial strain of an avirulent, non-pathogenic Clostridium ghonii that is capable of arresting the growth of, regressing or destroying one or more solid tumors. The present invention further relates to a composition comprising the derivative bacterial strain for targeted lysis of solid tumors. The present invention further relates to methods of producing derivative strains of C. ghonii by serial culturing in tumor bearing animals.